Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Breast Neoplasms 15Neoplasms 4Neoplasm Metastasis 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Tuberous Sclerosis 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Obesity 1Neuroendocrine Tumors 1Neoplasms by Site 1Lymphoma 1Lung Neoplasms 1Lung Diseases 1Kidney Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Breast Neoplasms, Male 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 11Nivolumab 7Sunitinib 6Cyclophosphamide 6aldesleukin 5Sorafenib 5Everolimus 5temsirolimus 4belzutifan 4atezolizumab 4Ipilimumab 4fludarabine 3cabozantinib 3Interferon-alpha 3Gene Expression Profiling 3Fluorouracil 3Docetaxel 3Cetuximab 3Busulfan 3valspodar 2sargramostim 2perifosine 2pazopanib 2ixabepilone 2entinostat 2ciforadenant 2belinostat 2Thiotepa 2Temozolomide 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Kidney Neoplasms × exemestane × Clear all
NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Novartis

Phase 1 Completed
79 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡